Show simple item record

dc.contributor.authorDiro, E
dc.contributor.authorBlesson, S
dc.contributor.authorEdwards, T
dc.contributor.authorRitmeijer, K
dc.contributor.authorFikre, H
dc.contributor.authorAdmassu, H
dc.contributor.authorKibret, A
dc.contributor.authorEllis, SJ
dc.contributor.authorBardonneau, C
dc.contributor.authorZijlstra, EE
dc.contributor.authorSoipei, P
dc.contributor.authorMutinda, B
dc.contributor.authorOmollo, R
dc.contributor.authorKimutai, R
dc.contributor.authorOmwalo, G
dc.contributor.authorWasunna, M
dc.contributor.authorTadesse, F
dc.contributor.authorAlves, F
dc.contributor.authorStrub-Wourgaft, N
dc.contributor.authorHailu, A
dc.contributor.authorAlexander, N
dc.contributor.authorAlvar, J
dc.date.accessioned2019-01-26T17:15:05Z
dc.date.available2019-01-26T17:15:05Z
dc.date.issued2019-01-17
dc.date.submitted2019-01-24
dc.identifier.citationA randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. 2019, 13 (1):e0006988 PLoS Negl Trop Disen
dc.identifier.issn1935-2735
dc.identifier.pmid30653490
dc.identifier.doi10.1371/journal.pntd.0006988
dc.identifier.urihttp://hdl.handle.net/10144/619327
dc.description.abstractVisceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a lower dose of AmBisome with miltefosine would show acceptable efficacy at the end of treatment.
dc.language.isoenen
dc.publisherPublic Library of Scienceen
dc.rightsArchived with thanks to PLoS Neglected Tropical Diseasesen
dc.titleA Randomized Trial of AmBisome Monotherapy and AmBisome and Miltefosine Combination to Treat Visceral leishmaniasis in HIV Co-infected Patients in Ethiopiaen
dc.identifier.journalPLoS neglected tropical diseasesen
refterms.dateFOA2019-03-04T14:17:46Z
html.description.abstractVisceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by the World Health Organization. The objective of the study was to assess if a combination of a lower dose of AmBisome with miltefosine would show acceptable efficacy at the end of treatment.


Files in this item

Thumbnail
Name:
A randomized trial of AmBisome ...
Size:
1.451Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record